Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01564264
Other study ID # SNEndometrialCa
Secondary ID
Status Recruiting
Phase N/A
First received March 23, 2012
Last updated August 29, 2014
Start date November 2012
Est. completion date December 2014

Study information

Verified date August 2014
Source Hamilton Health Sciences Corporation
Contact Waldo G Jimenez, MD MSc
Phone (905) 389-5688
Email Waldo.Jimenez@jcc.hhsc.ca
Is FDA regulated No
Health authority Canada: Hamilton Health Sciences
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if there is a difference between the lymphatic drainage of the cervix and corpus of the uterus after injecting a radiocolloid in the cervix and blue dye in the corpus of the uterus and to investigate the identification rate of sentinel nodes using this technique in patients with cancer of the uterus.


Description:

About 20 percent of women diagnosed with uterine cancer have spread outside of the uterus, mainly to the lymph nodes. If these metastases are recognized these women can still be cured with chemotherapy and radiation. Unfortunately different kind of imaging are not very sensitive in identifying patients with lymph node metastases and currently a complete removal of the lymph nodes in the pelvis and around the aorta is the gold standard diagnostic test. Sentinel node biopsy (SLNB) is a surgical technique that aims to identify the nodes that drain specifically the area were the tumor is located. A tracer is injected around the tumor and then the locoregional lymph nodes are tested for the presence of this tracer (blue dye and a radioactive substance). If the sentinel lymph node does not contain cancer, then there is a high likelihood that the cancer has not spread to any other area of the body.The benefits of doing sentinel node biopsy is that it decreases the potential complications associated with the removal of all the lymph nodes. This technique is the standard treatment for other cancers as breast cancer and melanoma and is emerging as a promising technique in gynecological cancers.

There is no agreement regarding the best technique to do SLNB in women with uterine cancer and this procedure is still at the stage of determining feasibility. Since 1996, there have been publications aiming to determine the most appropriate way to do sentinel node in uterine cancer. As the uterus cannot be reached preoperatively for tracer injection, the standard approach for other tumor sites of preoperative peritumoral injection of Technetium 99 followed by intraoperative injection of blue dye has needed to be modified. Blue dye with or without a radiocolloid have been administered either subserously (the uterus outer layer), cervically, dually, and hysteroscopically with a wide range of results in terms of identification rates of sentinel nodes. Certain factors as site of injection, volume and number of injections, interval time since injection to identification of sentinel nodes and surgical approach as laparotomy versus laparoscopy have been associated with the likelihood of identifying these nodes.

This study plans to determine the pattern of lymphatic drainage for the cervix and corpus of the uterus by injecting a different tracer in these 2 sites and also to incorporate all factors that have been proved to be associated with a better identification rate of sentinel nodes in a protocol in order to determine if this technique is feasible and reliable.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date December 2014
Est. primary completion date December 2014
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Women older than 18 years old

2. Endometrial cancer

3. Histologies: Grade 2 and 3 endometrioid adenocarcinoma, clear cell and papillary serous carcinoma

4. Suitable candidates for surgery

5. Clinically stage 1 or confined to the uterus

Exclusion Criteria:

1. Grade 1 endometrioid adenocarcinoma

2. Metastatic disease

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Procedure:
Sentinel Lymph Node Biopsy
Sentinel node biopsy after injections of 0.4 mci of Technetium 99 in the cervix and 4 mL of Patent Blue into the myometrium followed by standard retroperitoneal lymph node dissection

Locations

Country Name City State
Canada Juravinski Hospital, Juravinski Cancer Centre, McMaster University Hamilton Ontario

Sponsors (2)

Lead Sponsor Collaborator
Hamilton Health Sciences Corporation Juravinski Cancer Centre Foundation

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Location of Sentinel node Locations: internal iliac, external iliac, common iliac, paraaortic or presacral areas Location will be registered by type of sentinel nodes: blue nodes, reflecting the uterine pattern of lymphatic flow (after myometrial injection of blue dye)and hot nodes, reflecting cervical pattern of lymphatic flow (after injection of Technetium 99 in the cervix) Measurement for each participant will be performed between 2-4 hours after injecting Technetium 99 in the cervix No
Secondary Identification of metastatic lymph nodes by the sentinel node procedure Every participant will have a sentinel node procedure followed by a complete removal of the lymph nodes (gold standard), during the same surgery. Accuracy parameters of the sentinel node technique will be compared to the gold standard (complete lymphadenectomy) Measurement will be performed 2-4 hours after the cervical injection with Technetium 99 No
See also
  Status Clinical Trial Phase
Completed NCT02374411 - Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients N/A
Completed NCT00377520 - A Trial for Patients With Advanced/Recurrent Endometrial Cancer Phase 2
Recruiting NCT04063072 - ERAS (Enhanced Recovery After Surgery) Protocol Implementation in Piedmont Region for Hysterectomy. N/A
Terminated NCT01969396 - Evaluation of the Goldstein SonoBiopsy™ Catheter for Diagnosing Endometrial Pathology N/A
Terminated NCT00669422 - ChemoFx® PRO - A Post-Market Data Collection Study N/A
Completed NCT00231855 - Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers Phase 2
Completed NCT04679675 - Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial N/A
Completed NCT04351139 - Impact of the COVID-19 Pandemic in Gynecological Oncology
Completed NCT05004623 - Early Feasibility Study of the "Easy Light" Fluorecence Imaging System N/A
Completed NCT00112307 - Magnetic Resonance Imaging Guided Gynecologic Brachytherapy N/A
Completed NCT02454036 - Biobehavioral Intervention in Gynecologic Oncology Patients Phase 2
Completed NCT00188578 - Intensity Modulated Radiation Therapy - Gyne Cancer (GY03.2) Phase 1/Phase 2
Active, not recruiting NCT03951415 - Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer Phase 2
Completed NCT01654458 - A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer N/A
Completed NCT00190918 - A Trial for Patients With Gestational Trophoblastic Disease Phase 2
Completed NCT00050440 - Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma Phase 2
Completed NCT00250783 - Pre-Clinical Models in Gynecological Tumors A Tissue Repository
Recruiting NCT03624712 - Analysis and Optimization of Predictive and Therapeutic Models in Uterine Neoplasms
Completed NCT00628901 - A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE) Phase 4
Completed NCT00090389 - Acupuncture for Women's Health Conditions Phase 1